SCHEDULE: Armistice Capital Discloses 11.43% Stake in Aridis Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 11.43% of Aridis Pharmaceuticals, Inc. common stock as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed an amendment to their Schedule 13G.
• The filing discloses beneficial ownership of 5,096,251 shares of Aridis Pharmaceuticals, Inc. common stock.
• This represents 11.43% of the class of securities.
• The event triggering this filing was the acquisition of shares as of June 30, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake in Aridis Pharmaceuticals, Inc. The filing indicates a substantial investment without immediate aggressive action, suggesting a 'hold' or 'watchful waiting' stance.

Positives

• Significant ownership stake (11.43%) by a known investment manager, potentially signaling confidence in the company's future prospects.
• The filing is an amendment, suggesting ongoing management of the investment rather than a new, potentially disruptive, entry.

Negatives

• The filing does not provide specific details on the investment strategy or future intentions beyond holding the shares.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, which could imply a degree of separation in direct control.

Risks

• Potential for future changes in ownership or strategy by Armistice Capital, which could impact share price.
• The filing does not detail specific risks related to Aridis Pharmaceuticals, Inc. itself, focusing solely on ownership disclosure.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding Aridis Pharmaceuticals, Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant ownership disclosures via Schedule 13G filings are common in the biotechnology and pharmaceutical sectors, often indicating strategic interest from institutional investors. The 11.43% stake by Armistice Capital suggests a notable position in Aridis Pharmaceuticals, Inc., a company operating in a highly competitive and R&D-intensive industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially increasing investor confidence. However, future actions by Armistice Capital could also introduce volatility.
• Management of Aridis Pharmaceuticals, Inc.: The company's management will be aware of this substantial shareholder and may consider their interests in strategic decision-making.

Next Steps

• Monitor future filings from Armistice Capital for any changes in ownership or strategic actions.
• Observe Aridis Pharmaceuticals, Inc.'s performance and strategic developments in light of this significant shareholder.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. The disclosure of an 11.43% stake by Armistice Capital indicates significant investor interest but does not, on its own, provide enough information to warrant a buy or sell recommendation. The absence of aggressive language or immediate strategic plans suggests a period of observation. Investors should monitor future filings and company performance for further insights.

Keywords

Aridis Pharmaceuticals, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Investment Management, Common Stock, SEC Filing